SUMMARY
ESMO 2024 again yielded a wealth of information regarding gynaecological cancers. Here, the key findings of the latest clinical trials in this field are discussed.
(BELG J MED ONCOL 2024;18(8):325–331)
ESMO 2024 again yielded a wealth of information regarding gynaecological cancers. Here, the key findings of the latest clinical trials in this field are discussed.
(BELG J MED ONCOL 2024;18(8):325–331)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
